Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy.
نویسندگان
چکیده
BACKGROUND The frequency of skin tumors of all types and specifically of squamous cell carcinoma (SCC) is increased in heart transplantation (HT), but the predisposing risk factors are controversial. METHODS AND RESULTS We studied 300 patients (age 49+/-15 years, 258 men, mean follow-up 4.6 years, follow-up range 1 month to 12 years) who were receiving standard double (cyclosporin plus azathioprine) or triple (cyclosporin plus azathioprine plus prednisone) therapy. The first-year rejection score was calculated for endomyocardial biopsy samples (International Society for Heart and Lung Transplantation grade 0=0, 1A=1, 1B=2, 2=3, 3A=4, 3B=5, and 4=6) and used as an indirect marker of the level of immunosuppression. Multivariate analysis (Cox regression) included age at HT, sex, skin type, first-year rejection score, presence of warts and solar keratosis, lifetime sunlight exposure, and first-year cumulative dose of steroids. The incidence of skin tumors of all types increased from 15% after 5 years to 35% after 10 years after HT according to life-table analysis. Age at HT of >50 years (P:=0.03, RR=5.3), skin type II (P:=0.05, RR=2.6), rejection score of 19 (P:=0.003, RR=5.7), solar keratosis (P:=0.001, RR=6.9), and lifetime sunlight exposure of >30 000 hours (P:=0.0003, RR=7.6) were risk factors for SCC. CONCLUSIONS Older age at HT, light skin type, solar keratosis, greater sunlight exposure, and high rejection score in the first year were independently associated with an increased risk of SCC. The progressive increase in cancer frequency during follow-up and the association with high rejection scores suggest that both the length and level of immunosuppression may be relevant. Because cumulative immunosuppressive load is cumbersome to calculate, a high rejection score in the first year may provide a useful predictor for patients at risk.
منابع مشابه
Frequency of malignant skin tumors in renal transplant recipients in Imam Reza hospital of Mashhad, Iran
Background: The higher frequency of malignant skin tumors is of great significance in renal transplant recipients (RTRs) who should receive immunosuppressive therapy for a long time. This study was designed to determine the frequency of malignant skin tumors in RTRs in Imam Reza Hospital, Mashhad, Iran, in 2001-2002.Method: This descriptive study was performed on 322 recipients who were examine...
متن کاملبدخیـــمی بعد از پیــوند کلیــه
Background: Long term use of immunosuppressive therapy in transplant recipients in order to prevent acute and chronic rejection increases the long term risk of cancer. This study evaluates the incidence of different organs’ cancer after renal transplantation and immunosuppressive therapy. Methods: This is a retrospective analysis of malignant tumors in renal graft recipients with more than...
متن کاملMalignant skin lesions in transplant recipients
Several advances in the filed of organ transplantation in last decades have resulted in significant increase in the number and methods of transplantation. In this article various aspects of organ transplantation including immunosuppressive medications, common skin tumors seen in transplant recipients, possible mechanisms involved in increased incidence of skin tumors and finally preventive meas...
متن کاملSkin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern.
BACKGROUND/AIMS Skin tumours, in particular squamous-cell carcinomas (SCC), are the most common malignant conditions developing in transplant recipients. The aim of this study is to investigate the frequency and type of skin cancer in patients receiving immunosuppressive therapy after organ transplantation. METHODS Multivariate logistic regression analysis was performed on data of 243 renal t...
متن کاملRituximab Is Indispensable for Pediatric Heart Transplant Recipients Developing Post transplant Lymphoproliferative Disorders
Abstract Rituximab, an anti-CD20 agent, has been suggested as an effective strategy to deal with post transplant lymphoproliferative disorders (PTLD). In the current study, we aim to evaluate the efficacy of rituximab therapy in heart transplant population developing PTLD. A comprehensive search of the literature was performed to gather the available data on lymphoproliferative disorders oc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Circulation
دوره 102 19 Suppl 3 شماره
صفحات -
تاریخ انتشار 2000